Hear 20+ Presentations from Top Pharma at Drug Discovery Chemistry
As in the past, speaker participation by industry is once again very strong, with presentations from AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, Eli Lilly, F. Hoffmann-La Roche,
Genentech, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, and Sanofi. Preview the more than 20 presentations* below:
AbbVie
Utilization of a Fragment-based Approach in the Development of Orally Efficacious TNFα Inhibitors
Justin Dietrich, PhD, Principal Research Scientist I, Fragment Based Drug Discovery and DNA-Encoded Library Technologies
AstraZeneca
Scaffold Selection for Protein-Protein Interaction Modulation: Are There Any General Principles?
Leonardo De Maria, PhD, Principal Scientist
Structure-Free Elaboration of Fragments into Novel Allosteric MEK1 Binders
Paolo Di Fruscia, PhD, Senior Research Scientist, Medicinal Chemistry
Profiling of Covalent Inhibitors Using Biophysical Approaches
Stefan Geschwindner, Associate Director & Head of Biophysics
Turning Linear Peptide Substrates into Macrocyclic Inhibitors
Ranganath Gopalakrishnan, PhD, Associate Principal Scientist, New Modality & Medicinal Chemistry
Biogen
Discovering New Protein Interaction Partners of Gamma-Secretase with Photoaffinity Probes
Doug Johnson, PhD, Senior Director, Chemical Biology & Proteomics
Chemoproteomic Profiling of Covalent XPO1 Inhibitors to Assess Target Engagement and Selectivity
Jeffrey Martin, PhD, Scientist II, Drug Discovery
Boehringer Ingelheim
Evolution of BI-3406 – Getting a Foot in the Door between SOS1 and KRAS
Juergen Ramharter, PhD, Principal Scientist & Project Lead, Oncology Research
Eli Lilly & Co.
eDESIGNER: A Tool for Navigating the DNA-Encoded Libraries Chemical Space
Alfredo Martin, PhD, Senior Research Advisor, DCRT
F. Hoffmann-La Roche AG
Discovery of Novel g-Secretase Modulators (GSM) for the Potential Treatment of Alzheimer’s Disease
Hasane Ratni, PhD, Distinguished Scientist & Project Team Leader, Medicinal Chemistry
Genentech Inc.
Cyanopyrrolidine Inhibitors of USP7 Mediate Desulfhydration of the Active-Site Cysteine
Charlene Bashore, PhD, Principal Scientific Researcher
What Is AI Good for in Small Molecule Drug Discovery?
Jeff Blaney, Director Computational Chemistry & Cheminformatics, Computational Chemistry & Cheminformatics
Hijacking Autophagy by Co-Opting LC3 with Fragment Derived Ligands
Micah Steffek, MSc, Principal Scientific Researcher, Biochemical & Cellular Pharmacology
GlaxoSmithKline
Discovery of Small Molecule Inhibitors of sEH and RIPK1 Enabled by DNA-Encoded Library Technology: Two Case Studies
Carol Mulrooney, PhD, Investigator, Cheminformatics
Merck & Co., Inc.
An Orally Available Non-Nucleotide STING Agonist with Antitumor Activity: A Mechanistic Study
Gottfried Schroeder, PhD, Senior Scientist, Quantitative Biosciences
Novartis
Enabling Comprehensive and High-Throughput Exploration of Fragment Chemical Space by Using Broadband 19F NMR-Based Screening
Andreas Lingel, PhD, Senior Principal Scientist, Global Discovery Chemistry, NIBR
Characterization of the Recruitment of Proteins to Ligases by Molecular Glues
Charles A. Wartchow, PhD, Senior Principal Scientist, Global Discovery Chemistry, NIBR
Pfizer Inc.
Targeted Protein Degradation – Where Are We Going?
Adam Gilbert, PhD, Senior Director, Discovery Sciences, Design & Synthesis Sciences
Toward the Assembly and Characterization of an Encoded Library Hit Optimization Platform: Bead-Assisted Ligand Isolation for Mass Spectrometry (BALI-MS)
Anokha S. Ratnayake, PhD, Principal Scientist, Design and Synthesis Sciences, DNA Encoded Library Technology Group
Determining Affinity from Irreversible Thermal Shift
Justin Hall, PhD, Principal Scientist, Structural Biology & Biophysics
Sanofi
Automated Design of Macrocycles for Therapeutic Applications: From Small Molecules to Peptides and Proteins
Stefan Guessregen, PhD, Principal Scientist, R&D Integrated Drug Discovery
* As of 3/10/21 – Please see individual agenda pages for most up-to-date list of speakers